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Cryopyrin-associated periodic
fever syndrome manifesting as
Tolosa-Hunt syndrome
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Abstract
Background: Tolosa-Hunt syndrome (THS) is characterized by unilateral orbital pain, ipsilateral oculomotor paresis and
a prompt response to treatment with corticosteroids. Several reports have demonstrated that the clinical features of
THS are not specific to one causal aetiology and can lead to misdiagnosis.
Case report: We report the case of a patient diagnosed with THS after an episode of unilateral orbital pain and diplopia
with demonstration of granulomatous inflammation of both cavernous sinus on cerebral magnetic resonance imaging and
an immediate response to treatment with corticosteroids. Progression of the disease over the following years, accom-
panied by increasing signs of inflammation on cerebral magnetic resonance imaging and cerebrospinal fluid pleocytosis,
led to further diagnostic tests. Genetic analyses revealed a heterozygote low-penetrance mutation (Q703K) of the
cryopyrin/NLRP3 gene compatible with a cryopyrin-associated periodic fever syndrome.
Discussion: This case report demonstrates that THS can be a central nervous system manifestation of cryopyrin-
associated periodic fever syndrome, which therefore represents a differential diagnosis of THS, even in elderly patients.
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Background
Tolosa-Hunt syndrome (THS) is characterized by uni-
lateral orbital pain, ipsilateral oculomotor paresis and a
rapid response to treatment with corticosteroids. In
1966, Smith and Taxdal (1) were the first to use the
name Tolosa-Hunt syndrome based on the observa-
tions made by Tolosa (2) and Hunt et al. (3). The
aetiology of this syndrome is still unknown.
Histopathological studies have shown a non-specific
granulomatous inflammation of the cavernous sinus
or orbital apex (4). In 1988 the International
Headache Society (IHS) defined the diagnostic criteria
of THS as episode(s) of unilateral orbital pain for an
average of eight weeks if untreated, accompanied by
paresis of the third, fourth and sixth cranial nerves,
which may coincide with the onset of pain or follow
it within a period of up to two weeks, with the pain
being relieved within 72 hours after initiation of treat-
ment with corticosteroids. Other causative lesions had
to be excluded by neuroimaging (5). This classification
was criticized because it did not always lead to a correct
diagnosis and did not reflect the complexity of this syn-
drome and its various differential diagnoses (6). The
revised IHS headache classification, published in
2004, required that the granuloma were demonstrated
by magnetic resonance imaging (MRI) or a biopsy
sample, the pain and paresis responded to treatment
with steroids, and other causes were excluded by appro-
priate investigations and follow-up. The 2004 criteria
are given in Table 1 (7).
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A review of the published literature on THS from
1988 to 2002 demonstrated that only 21% of 208
reported cases were classified as THS based on these
criteria (4). Possible differential diagnoses include
recurrent cranial neuropathy, lymphoma, idiopathic
hypertrophic cranial pachymeningitis, vasculitis, infec-
tious disease, a tumour or sarcoidosis. This illustrates
that the clinical features of THS are not specific, do not
guarantee a correct diagnosis and may even can create a
dangerous sense of false security, as illustrated in the
following case report.
Case report
In June 2009, a 63-year-old Croatian man developed,
within days, unilateral, left-sided, unbearable orbital
pain accompanied by diplopia. The double vision
ceased after one week, but the pain persisted and led
to a first neurological consultation. The differential
diagnosis of a trigemino-autonome headache was con-
sidered; however, a therapeutic trial with high-dose
oxygen, sumatriptan and indomethacin gave no pain
relief. Lumbar puncture results showed a normal cere-
brospinal fluid (CSF) cell count (3 cells/ml) and normal
CSF protein, but positive oligoclonal bands. C reactive
protein (CRP) and the erythrocyte sedimentation rate
(ESR) were both increased, although there was no
other evidence of rheumatological disease. Cranial
MRI demonstrated a granulomatous inflammation of
both cavernous sinus, which was more pronounced on
the left side, and a granulomatous inflammation of the
anterior clinoid process and the cerebellopontine angle.
The diagnosis of THS was made and treatment
with corticosteroids (glucocorticoid, prednisolone
100mg/day) was started. This immediately relieved
the pain, supporting the diagnosis of THS.
The sinistral orbital pain reoccurred intermittently
without diplopia when the steroid treatment was
reduced and always showed an immediate response to
the patient’s self-medication with a single dose of 20mg
prednisolone. However, the symptoms worsened with
almost daily headache and nightly pain attacks from
December 2014 and therefore cranial MRI was
repeated and showed increasing signs of inflammation
with a contrast-enhancing mass in both cavernous
sinus, the left side of the basal dura and the left ten-
torium (Figure 1A), and an oedema in the left
temporal lobe (Figure 1B). Lumbar puncture showed
a CSF pleocytosis (24 cells/ml; 57% lymphocytes, 29%
neutrophils and 10% monocytes) and increased CSF
protein (110mg/dl). CRP and ESR were repeatedly
elevated.
This disease progression led to admission to our
department. The patient was treated on admission
with non-steroidal anti-inflammatory drugs, but no
glucocorticoid. A neurological examination still
showed no neurological deficit, but the patient reported
daily, left-sided retro-orbital headache. A repeated
lumbar puncture showed a normal CSF cell count
(4 cells/ml) and normal CSF glucose, but increased
CSF protein (86mg/dl) and intrathecal IgG, IgA and
IgM synthesis with positive oligoclonal bands.
Angiotensin-converting enzyme was normal in the
serum samples and CSF, s-IL2 receptor was mildly
increased to 842 kU/l (standard value 158–623 kU/l)
in serum samples, but a positron emission
tomography-computed tomography scan with
18F-fluorodeoxyglucose showed no evidence of an
organic manifestation of sarcoidosis. Antibody indices
of HSV-, VZV-, CMV-, measles-, rubella- and lues-
IgG, and borrelia-IgM and -IgG were normal; micro-
biological analysis showed no sign of central nervous
system (CNS) tuberculosis with negative polymerase
chain reaction, culture and microscopy. Inflammatory
markers in serum, including CRP, ESR and serum
amyloid A, were normal.
The constellation of recurrent episodes with
increased inflammatory markers, unusual but distinct
MRI features with meningeal contrast enhancement,
the immediate response to treatment with glucocortic-
oids and temporary CSF pleocytosis prompted us to
consider a CNS manifestation of an autoinflammatory
syndrome, specifically a cryopyrin-associated periodic
Table 1. Diagnostic criteria of Tolosa-Hunt syndrome (7).
 One or more episodes of unilateral orbital pain persisting for
weeks if untreated
 Paresis of one or more of the third, fourth and/or sixth cra-
nial nerves and/or demonstration of granuloma by magnetic
resonance imaging or a biopsy sample
 Paresis coinciding with the onset of pain or following within
two weeks
 Pain and paresis resolve within 72 hours when treated ade-
quately with corticosteroids
 Other causes have been excluded by appropriate
investigations
Note
Other causes of painful ophthalmoplegia include tumours, vascu-
litis, basal meningitis, sarcoidosis, diabetes mellitus and oph-
thalmoplegic ‘migraine’
Comments
Some reported cases of Tolosa-Hunt syndrome have additional
involvement of the trigeminal nerve (commonly the first div-
ision) or optic, facial or acoustic nerves. Sympathetic innerv-
ation of the pupil is occasionally affected
The syndrome has been shown to be caused by granulomatous
material in the cavernous sinus, superior orbital fissure or
orbit in some patients who had a biopsy sample taken.
Careful follow-up is required to exclude other possible
causes of painful ophthalmoplegia
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fever syndrome (CAPS). Genetic testing for the most
prevalent syndromes (including familial Mediterranean
fever syndrome, tumour necrosis factor receptor I asso-
ciated periodic syndrome and CAPS) were performed
and showed a heterozygote carrier status of a glutam-
ine703 (CAG)> lysine (AAG)/p.Gln703Lys/Q703K
substitution encoded by exon 3 of the NLRP3 gene,
confirming the diagnosis of CAPS. The patient’s past
medical history revealed (apart from headache) no
other typical systemic manifestation of CAPS, such as
myalgia, arthralgia, recurrent fever episodes, urticarial
rash or gastrointestinal symptoms. An eye examination
showed no ocular manifestation such as papillitis,
conjunctivitis or uveitis, but audiometry revealed a
bilateral high-frequency dip, indicating sensorineural
hearing loss.
Finally, the diagnosis of CAPS-associated CNS
inflammation manifesting as THS was made and
high-dose corticosteroid treatment (a total of 5 g of
methylprednisolone, followed by a slow oral reduction)
was administered. This immediately stopped the head-
ache. Six weeks later the patient was still asymptomatic
and a follow-up MRI scan showed improvement with
diminished contrast enhancement and regression of
the oedema (Figure 2). As a result of recently
occurring headache attacks with repeated glucocortic-
oid treatment and evidence for sensorineural hearing
loss, anti-interleukin-1 treatment is currently being
evaluated.
Discussion
This case report reflects the difficulties in establishing
the diagnosis of THS. At the start of treatment, the
diagnosis of THS was made on the basis of: (a) the
initial clinical presentation with unilateral orbital pain
and double vision; (b) the demonstration of a granu-
lomatous inflammation of both cavernous sinus (more
pronounced on the left side) on MRI; and (c) the imme-
diate resolution of pain after treatment with cortico-
steroids. The patient later developed recurrent
episodes of unilateral orbital headache without diplo-
pia, which promptly disappeared on treatment with
corticosteroids. Apart from increased inflammatory
markers, no other associated symptom or clinical find-
ing was present. Thus the patient completely fulfilled
the criteria for THS. Progression of CNS inflammation
years later with distinct MRI features, including an
additional contrast-enhancing mass in the left side of
the basal dura and the left tentorium and an oedema in
the left temporal lobe, prompted further diagnostic
workup. Molecular genetic analysis showed a Q703K
mutation encoded by exon 3 of the NLRP3 gene, which
is associated with CAPS.
CAPS are a group of rare, systemic monogenetic
inherited autoinflammatory diseases. They encompass
familial cold-induced autoinflammatory syndrome,
Muckle–Wells syndrome and neonatal-onset
multisystem inflammatory disease/chronic infantile
Figure 1. (a) Axial T1-weighted image after the intravenous administration of a gadolinium-based contrast medium showing pro-
nounced tentorial thickening and meningoencephalitic inflammation with granulomatosis-like enhancement. (b) Axial T2-weighted
sequence demonstrating temporo-basal oedema.
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neurological, cutaneous and articular syndrome (8,9).
They are all caused by gain-of-function mutations in
exons 3, 4 or 6 of the NLRP3 gene (formerly named
CIAS1) encoding the protein cryopyrin, a component
of the NLRP3 inflammasome. Overproduction of the
proinflammatory cytokine interleukin-1 beta leads to
multisystemic inflammation affecting the skin, eye,
joints, bones and CNS (8). Patients may present with
variable degrees of recurrent unprovoked episodes of
fever, abdominal pain, myalgia, arthralgia and urticar-
ial rash, as well as conjunctivitis or uveitis (10). CNS
manifestations may also occur and include recurrent
aseptic meningitis, increased intracranial pressure,
headache syndromes, papilloedema and seizures, as
well as vision and sensorineural hearing loss. In one
report it was shown that patients with classical
NLRP3 mutations and CNS manifestations mainly suf-
fered from headache syndromes and papilloedema (9).
We have expanded the spectrum of CAPS-associated
neurological manifestations in a large cohort of
patients with low-penetrance mutations (the Q703K
substitution and V198M substitution in exon 3 of the
NLRP3 gene). Headache syndromes were also present
in more than half of the mutation-positive patients.
In addition, cranial nerve involvement was a distinct
feature of CAPS-associated neurological manifest-
ations in these patients (8). One patient showed distinct
MRI features similar to the patient presented here.
Both displayed tentorial thickening and inflammation
with contrast enhancement as well as pronounced intra-
cerebral oedema distinct from THS. Table 2 gives an
overview of the CAPS phenotype according to different
NLRP3 gene mutations.
Apart from CNS manifestations and recurrent ele-
vation of inflammatory markers, we found little evi-
dence for a systemic manifestation of CAPS. Atypical
presentation and manifestation later in life can make
neurological manifestations in patients carrying low-
penetrance cryopyrin/NLRP3 mutations a difficult
diagnostic challenge. Furthermore, neurologists are
not usually familiar with CAPS. This constellation
may lead to misdiagnosis and there may be a large
number of unreported or misdiagnosed patients. Our
case report illustrates that CAPS should be considered
in patients with THS and recurrent episodes of aseptic
meningoencephalitis. Both CAPS and THS show epi-
sodic exacerbations and respond rapidly to treatment
with glucocorticoids. Careful evaluation of the patient’s
medical history for additional unexplained recurrent
symptoms, such as myalgias/arthralgias, urticarial
rash, uveitis/conjunctivitis and repeated elevation of
inflammatory markers, is necessary.
At the time of the initial presentation, the patient
fulfilled the ICHD-II criteria for THS. However, the
later ICHD-3 beta criteria for THS strengthened
the diagnostic role of MRI and attenuated the role of
Figure 2. (a) Six weeks after administration of glucocorticoids, repeated magnetic resonance imaging showed improvement of
the central nervous system inflammation with reduced contrast enhancement on axial T1-weighted image after the intravenous
administration of a gadolinium-based contrast medium with (b) remission of the oedema in the left temporal lobe on an axial
T2-weighted image.
Höhne et al. 1395
the therapeutic response to treatment with glucocortic-
oids (13). Retrospectively, the patient’s first symptoms
would still fulfil the current ICHD-3 beta criteria, but,
later on, the clinical course changed and revealed the
misdiagnosis. Therefore we recommend considering a
period of follow-up examination before diagnosing
THS, including repeated MRI and CSF diagnostics
and repeated examinations for possible systemic mani-
festations of autoinflammatory disease.
Based on our experience with the reported patient, it
might even be the case that an unknown number of
patients diagnosed with THS and fulfilling all the IHS
criteria may have CAPS as the underlying cause.
Consequently, we recommend molecular genetic testing
in patients with THS and additional symptoms or signs
suggestive of CAPS, especially because additional treat-
ment options other than glucocorticoids are available
for patients with CAPS.
Clinical implications
. In patients with Tolosa-Hunt syndrome, careful evaluation of their medical history with additional unex-
plained recurrent symptoms, such as myalgias/arthralgias, urticarial rash, uveitis/conjunctivitis and repeated
elevation of inflammatory markers, is necessary.
. Molecular genetic testing should be considered in patients with THS and additional unexplained symptoms,
even in older patients, because alternative therapeutic options (e.g. anti-interleukin-1 treatment) are avail-
able for cryopyrin-associated periodic fever syndrome.
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Table 2. Neurological and systemic manifestations of low-penetrance mutations in the NLRP3 gene based on the literature (8,11,12)
and the patient described here.
Low-penetrance











Q703K þþþ þþ þþþ þþþ þþ þ þþ –
V198M þþþ – þ þ þ þþþ þþþ þþ
þþþ: severe; þþ: moderate; þ: mild; :none; CN: cranial nerve; CNS: central nervous system.
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